A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19.

ABSTRACT: Tetracyclines exhibit anti-viral, anti-inflammatory, and immunomodulatory activities via various mechanisms. The present study investigated the efficacy and safety of demeclocycline in patients hospitalized with mild-to-moderate COVID-19 via an open-label, multicenter, parallel-group, randomized controlled phase 2 trial. Primary and secondary outcomes included changes from baseline (day 1, before the study treatment) in lymphocytes, cytokines, and SARS-CoV-2 RNA on day 8. Seven, seven, and six patients in the control, demeclocycline 150 mg daily, and demeclocycline 300 mg daily groups, respectively, were included in the modified intention-to-treat population that was followed until day 29. A significant change of 191.3/μL in the number of CD4⁺ T cells from day 1 to day 8 was obs

SUBMITTER: Iwahori K 

PROVIDER: S-EPMC10447520 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature